Daily Archives: June 12, 2019

Merrell Launches “One Day. One World. One Trail.” to Showcase the Unifying Power of the Outdoors

ROCKFORD, Mich., June 12, 2019 (GLOBE NEWSWIRE) — To celebrate the global diversity that exists on the trail, outdoor brand Merrell has launched their “One Day. One World. One Trail.” project. On Saturday, April 27, across 17 countries, Merrell sent 23 photographers and filmmakers out to the trail to showcase those experiencing natural spaces and how the trail unites us all.

The individuals featured are not paid models, athletes, or social media influencers. They are real people who were out enjoying the outdoors and stopped to share a moment with the creatives producing the project.Merrell_1H19_OneDayOneWorldOneTrail

“The trail is a great unifier, and our goal with the One Trail project is simply to demonstrate that,” says Strick Walker, CMO at Merrell. “We hope this global snapshot of a day on the trail will inspire others to get out there. We can all benefit from time spent in nature and the power of the trail.”

Two films as well as individual imagery from the 17 countries featured in the project can be viewed at Merrell.com/OneTrail. The full list of countries and trails included in the creative are listed below. In November 2018, Merrell launched the first iteration of their One Trail project featuring all 50 states within the US, followed by another chapter in June 2019 showcasing real people enjoying Canada’s trails.

In addition to collaborating alongside a diverse set of global photographers and filmmakers, Merrell worked with Tim Kemple and Camp4 Collective to produce the project.

“There are very few common languages in this world. A smile. A laugh. A feeling of moving forward together. So capturing these in a spontaneous, genuine way was essential for this project,” says Tim Kemple, Co-Founder and Director at Camp4 Collective. “No matter your language, religion, size, color — when we’re on the trail, we share common ground. And recognizing that idea is pretty profound right now.”

For more information or multimedia assets, please reach the contacts below.

ABOUT MERRELL
Merrell® exists to give you all you really need to discover the simple yet profound power of the trail. We believe the trail is for everyone. Our goal is to provide thoughtfully designed, rigorously tested products that over-deliver on performance, versatility and durability. Because when you’ve got air in your lungs and good shoes on your feet, you’ve got everything you need. Visit Merrell.com or follow us on social at @merrell and @merrelloutside.

MEDIA CONTACTS
Finn Partners / merrell@finnpartners.com
Lauren King / Lauren.King@merrell.com

Countries and Trails:

  • 17 countries, including three locations in Canada and the US
  • 23 photographers across the globe
  • Countries, including trail:
    1.   Argentina, Patagonia
    2.   Austria, Jägersee, Kleinarl
    3.   Australia, Tasmania, Tasman Peninsula, Cape Hauy track
    4.   Canada, Baffin Island to Kimmirut
    5.   Canada, Canmore, Alberta, Lady Macdonald Hiking Trail
    6.   Canada, British Columbia, Terrace Mountain Hiking Trail
    7.   China, Hong Kong, Lion Rock
    8.   China, Sichuan Province, Mount Siguniang Nature Reserve
    9.   France, Les Calanque of Marseyllevert and Sormiou
    10. India, Kundalika Valley and Lohagad Fort
    11. Eastern India, Nagalapuram, Andhra Pradesh
    12. Italy, Dolomites, Cima Capi – Riva del Garda and Monte Colodri, Arco
    13. Nepal, Anapurna Circuit
    14. New Zealand, Wanaka, Roy’s Peak Track
    15. Peru, Caraz, Ancash, Laguna 69
    16. Poland, Mt. Sniezka
    17. Portugal, Vicentina Route, Almograve to Praia da Amália
    18. Scotland, Pentland Hills near Edinburgh
    19. South Africa, Cape Town
    20. Sweden, Kullaberg Nature Reserve, Höganäs
    21. USA, Los Angeles, Sandstone Peak
    22. USA, Kentucky, Red River Gorge, Daniel Boone National Forest, Auxier Ridge Area Trails
    23. USA, Oregon, Smith Rock, Terrebonne

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e089c833-13bd-482d-83a6-abafab36dfea

Teledyne e2v’s Emerald 67M, Ultra-high Resolution Image Sensor Now Available

The sensor uses TowerJazz’s best-in-class 2.5µm global shutter pixel that doubles the resolution for the same optical format

GRENOBLE, France and MIGDAL HAEMEK, Israel, June 12, 2019 (GLOBE NEWSWIRE) — Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and global innovator of imaging solutions, and TowerJazz [Nasdaq: TSEM], the global specialty foundry leader, announce that Teledyne e2v’s Emerald™ 67M image sensor, designed for ultra-high resolution electronics inspection, high-end surveillance and microscopy is now available. Emerald-XL-1_web

The sensor is a member of Teledyne e2v’s Emerald family and features TowerJazz’s smallest in the world 2.5µm low-noise global shutter pixel, on TowerJazz’s 65nm platform, in its Uozu, 300mm Japanese manufacturing facility.  The pixel is integrated with a unique light pipe technology, offering superb angular response, more than 80dB shutter efficiency, in a significantly small size, and extremely low noise (one electron).  This unique pixel architecture provides cutting edge performance that enables improved manufacturing yields, through detection of smaller defects.

The Emerald family of sensors, solely manufactured by TowerJazz, provides customers with an unprecedented set of features and are all suitable for high-speed interface systems including 10GigE, CoaXPress, Camera Link, and Camera Link HS.  Special features include HDR modes with up to 120dB dynamic range and also a unique Region Of Interest (ROI) mode which allows multiple ROI to be captured under different exposure conditions, further improving the dynamic range of an image.

Emerald 67M has a square shape with 8k resolution per side, enabling 95% utilisation of the image area for the next generation of display manufacturing, gen 10.5. The ultra-high resolution optimizes vision system movements in large product inspection, reducing system complexity and removing instabilities. It is available in two different speed grades (ultra-high speed, 60fps and high speed, 30fps).

Rafael Romay, Vice President of Professional Imaging at Teledyne e2v, said “The Emerald 67M is the first sensor of its kind and is enjoying strong interest in inspection applications due to its ultra-high resolution and fast speed. It also shares many of the smart features within other Emerald sensors making it easier to deploy within vision systems. The great technology innovation and support from TowerJazz allowed us to bring to market this best-in-class solution, customized to product and application needs.”

Dr. Avi Strum, TowerJazz Senior Vice President and General Manager of the Sensor Business Unit said, “Teledyne e2v’s design and supply chain along with TowerJazz’s state of the art 65nm process have again brought a game changing sensor to machine vision applications. We are proud to have developed this together and look forward to further collaboration with Teledyne e2v to serve the machine vision market.”

For sample and evaluation kit requests or more information visit the product webpage.
For more information about TowerJazz’s CMOS image sensor technology offering, please visit here.

For media enquiries, please contact:
Jessica.Broom@teledyne.com | + 44 (0)1245 453607

TowerJazz Company Contact:
Orit Shahar | +972-74-7377440 | oritsha@towersemi.com


Notes to Editors:


About Teledyne e2v

Teledyne e2v is part of the Teledyne Imaging Group. Their innovations lead developments in healthcare, life sciences, space, transportation, defence and security and industrial markets. Teledyne e2v’s unique approach involves listening to the market and application challenges of customers and partnering with them to provide innovative standard, semi-custom or fully-custom imaging solutions, bringing increased value to their systems. For more information www.teledyne-e2v.com.

About Teledyne Imaging
Teledyne Imaging is a group of leading-edge technology companies aligned within the Teledyne brand. With unrivalled expertise across the electromagnetic spectrum and decades of experience, the group offers world-leading capabilities in sensing, signal generation and processing. The collective delivers innovative solutions to aerospace, defense, geospatial, machine and industrial vision, medical and life sciences, semiconductors and MEMs. For more information, visit teledyneimaging.com.

About TowerJazz
Tower Semiconductor Ltd. (NASDAQ: TSEM, TASE: TSEM) and its subsidiaries operate collectively under the brand name TowerJazz, the global specialty foundry leader. TowerJazz manufactures next-generation integrated circuits (ICs) in growing markets such as consumer, industrial, automotive, medical and aerospace and defense. TowerJazz’s advanced technology is comprised of a broad range of customizable process platforms such as: SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, integrated power management (BCD and 700V), and MEMS. TowerJazz also provides world-class design enablement for a quick and accurate design cycle as well as Transfer Optimization and development Process Services (TOPS) to IDMs and fabless companies that need to expand capacity. To provide multi-fab sourcing and extended capacity for its customers, TowerJazz operates two manufacturing facilities in Israel (150mm and 200mm), two in the U.S. (200mm) and three facilities in Japan (two 200mm and one 300mm) through its partnership with Panasonic Semiconductor Solutions Co. LTD. For more information, please visit: www.towerjazz.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6994c34f-11b1-4006-aea1-d8a4d8607242

SignalFx Raises $75 Million to Fuel Demand for its Cloud Monitoring Platform

SAN MATEO, Calif., June 12, 2019 (GLOBE NEWSWIRE) — SignalFx, the leader in real-time cloud monitoring and observability for infrastructure, microservices, and applications, today announced it has raised $75 million in Series E funding led by Tiger Global Management with participation from existing investors. The primary equity financing brings total funding raised to $179 million and will accelerate product development and the company’s rapid global expansion.

SignalFx’s growth comes as organizations have increasingly turned to cloud-native technologies such as microservices, containers, Kubernetes and serverless functions to speed their rate of innovation. SignalFx’s annual revenues have increased by a compound annual growth rate of 170 percent since sales began in 2015 as traditional monitoring tools have failed to keep pace with new requirements for speed, scale and automation. According to Gartner, by 2022, more than 75 percent of global organizations will be running containerized applications in production, up from fewer than 30 percent today.

SignalFx’s customer list has grown to include hundreds of market-leading brands in an array of industry verticals and geographies, from ecommerce, retail, transportation, enterprise, and technology to finance, consumer products, and health care. Customers include both high-tech organizations born in the cloud, such as Acquia, Carbon Black, Cloudreach, Freecharge, HubSpot, Kayak, Namely, Rappi, Shutterfly, Square, and Yelp, as well as traditional enterprises investing in digital transformation, such as Amtrak, athenahealth, Lululemon, NBCUniversal, and the Warehouse Group.

“The addition of Tiger Global Management to our team comes at an important time for SignalFx,” said Karthik Rau, CEO, SignalFx. “SignalFx is at an inflection point in its growth as organizations are investing aggressively in their cloud and digital transformation initiatives and reevaluating their systems management and monitoring strategies. The additional capital from this financing allows us to invest even more in our industry-leading products while also extending our go-to-market reach to more organizations around the world.”

SignalFx pioneered the use of streaming analytics for monitoring cloud infrastructure and applications, building a highly scalable, low latency platform that can process massive amounts of data using advanced data science to accurately identify patterns of behavior and alert on anomalies in seconds. In November the company further increased the technical leadership of its platform by adding Microservices APM™, the industry’s first real-time application performance monitoring solution designed to accelerate the troubleshooting and triaging of microservices-based applications. Microservices APM is powered by a unique NoSample™ architecture that observes every transaction—instead of just a small random sample—and accurately reports on every anomaly.

SignalFx was founded in 2013 by the original developers of Facebook’s metrics-based monitoring solution (ODS), one of the industry’s first DevOps monitoring platforms. During the last two years, the company has expanded its executive bench to include: Chief Operating Officer Mark Cranney, Chief Financial Officer Mark Resnick, Executive Vice President of Engineering Leonid Igolnik, Chief Marketing Officer Tom Butta, and Chief People Officer Laura MacKinnon.

In February, SignalFx announced the opening of a Research and Development Support Office in Krakow, Poland and expanded sales operations throughout EMEA and Australia. Global headcount is now 270 and growing.

About SignalFx

SignalFx, the only real-time cloud monitoring platform for infrastructure, microservices, and applications, collects and analyzes metrics and traces across every component in your cloud environment. Built on a massively scalable streaming architecture, SignalFx applies advanced analytics and data-science-directed troubleshooting to let operators find the root cause of issues in seconds. SignalFx is trusted by leading enterprises across most every industry sector. SignalFx is backed by Andreessen Horowitz, Charles River Ventures, General Catalyst, and Tiger Global Management.

For More Information:

Contact Mike Moeller, (408) 439-4169

*Gartner, Inc., Best Practices for Running Containers and Kubernetes in Production, Arun Chandrasekaran, 25 February 2019.

Crown Bioscience Announces Four New Preclinical NASH Models In Development

– Reaffirms Commitment to NASH Drug Discovery –

SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, today announced four new preclinical translational NASH models in development.

NASH is a degenerative liver disease that affects up to 12 percent of the adult population worldwide and without treatment is expected to become the leading cause for liver transplant by 2020. Today there are no approved drugs to treat NASH.

CrownBio is steadfast in its commitment to the NASH drug development community through continued research and development of translatable preclinical NASH models. This dedicated investment will result in the availability of four new models over the next 12 months.

The models include:

  • A chemically-enhanced murine model using carbon tetrachloride
  • Modified diet models such as amylin, MCD or other choline deficient diets which more closely mimic a western diet and exacerbates fibrosis
  • An accelerated diet-induced murine model
  • An accelerated diet-induced NHP model

These models will join the existing CrownBio NASH platform which include the MS-NASH model (formerly known as FATZO), a next generation murine model of obesity, dysmetabolism and diabetes that exhibits accelerated and exacerbated liver fibrosis under administration of carbon tetrachloride, and a spontaneously obese, dysmetabolic, and diabetic NHP model, which develops NAFLD/NASH similarly to humans.

“We continue to demonstrate our deep commitment to developing new and relevant preclinical models of NASH,” said Jim Wang, senior vice president cardiovascular and metabolic disease research. “The addition of these new models will establish a market-leading platform to accelerate NASH drug discovery.”

Supporting International NASH Day 2019:
To support NASH Day, CrownBio will host a webinar that presents solutions to the challenges associated with preclinical modeling of NASH. CrownBio will donate $25 for each person that attends the webinar to the Global Liver Institute.

Visit https://www.crownbio.com/nash-day-webinar to register.

New NASH Research:
CrownBio recently presented two posters on the MS-NASH model at the 79th Scientific Sessions of the American Diabetes Association earlier this week.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

For more information visit:

https://www.crownbio.com
https://www.jsrlifesciences.com

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
marketing@crownbio.com

NTS Ventures และ IHMA ได้ประกาศโปรแกรมสำคัญที่มุ่งเน้นการเฝ้าระวังการดื้อยาต่อต้านเชื้อรา: STAR (Susceptibility Trends in Antifungal Resistance)

SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) — NTS Ventures (NTS) ซึ่งเป็นห้องปฏิบัติการการวิจัยทางคลินิกเกี่ยวกับวิทยาเชื้อราและ International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA) ซึ่งเป็นห้องปฏิบัติการจุลชีววิทยาทางคลินิกด้านการต่อต้านการติดเชื้อกลางซึ่งมีบริการครบวงจร ได้ประกาศข้อตกลงความร่วมมือที่จะมอบโปรแกรมเฝ้าระวังการดื้อยาต่อต้านเชื้อราแบบใหม่ซึ่งเรียกว่า STAR ให้กับอุตสาหกรรมเภสัชกรรม นอกจากความชำนาญที่มอบโดย NTS และ IHMA แล้ว โปรแกรม STAR ยังได้รับการสนับสนุนอย่างมากด้วยการรับห้องปฏิบัติการผู้นำทางความคิด (KOL) จากทั่วโลกมาเข้าร่วม เมื่อการดื้อยาของเชื้อราเพิ่มสูงขึ้นและมีความเปลี่ยนแปลงทางการระบาดวิทยา STAR จะเฝ้าระวังความผันผวนและแนวโน้มของการดื้อยาของเชื้อราและการระบาดวิทยาอย่างใกล้ชิดเมื่อเวลาผ่านไป โปรแกรมนี้จะเป็นเครื่องมือที่ยอดเยี่ยมสำหรับหน่วยงานของรัฐ บริษัทเทคโนโลยีชีวภาพ และบริษัทเภสัชกรรมในการต่อสู้กับการดื้อยาต่อต้านเชื้อรา กลุ่มแบคทีเรียที่ได้จากการทดลองทางคลินิกซึ่งเก็บรวบรวมตามขั้นตอนโดย STAR จะประกอบด้วยยีสต์สายพันธุ์สำคัญทั้งหมด (รวมถึง Candida auris ซึ่งเป็นเชื้อสายพันธุ์ใหม่) และเชื้อราที่มีลักษณะเป็นแท่งยาว เช่น Aspergillus spp และเชื้อราสายพันธุ์ที่หายากกว่าและแพร่กระจายได้อย่างรวดเร็วมาก เช่น Mucor spp., Rhizopus spp.และอื่นๆ

การพัฒนาสารต่อต้านเชื้อราใหม่ๆ กำลังมีจำนวนเพิ่มมากขึ้น ด้วยเหตุนี้ STAR จึงให้การสนับสนุนตัวยาเหล่านี้เพื่อให้แน่ใจว่าการต่อสู้กับการดื้อยาต่อต้านเชื้อรามีประสิทธิภาพมากขึ้นและเพื่อช่วยมอบเวลาอันสำคัญในการลดและกำจัดการดื้อยาใหม่ๆ ในที่สุด  ข้อตกลงระหว่าง NTS และ IHMA จะทำให้บริษัทเภสัชกรรมและเทคโนโลยีชีวภาพทั้งหมดสามารถเข้าถึงโปรแกรม STAR ได้อย่างมีประสิทธิภาพทั้งในด้านต้นทุนและเวลา “โปรแกรม STAR เป็นความริเริ่มการเฝ้าระวังที่ไม่เหมือนใครในการบันทึกข้อมูลลักษณะการติดเชื้อราร้ายแรง ซึ่งรวมถึง Candida auris และ Aspergillus ซึ่งดื้อยาต่อต้านเชื้อราทั่วไปและยาแบบทดลองที่ยังคงอยู่ระหว่างขั้นตอนการพัฒนา” Dr. Mahmoud Ghannoum, ผู้ก่อตั้ง NTS Ventures กล่าว

“โปรแกรมเฝ้าระวัง STAR จะให้ข้อมูลที่สำคัญเกี่ยวกับโรคราร้ายแรงและยังให้ข้อมูลที่เกี่ยวข้องและทันสมัยเกี่ยวกับสารต่อต้านเชื้อราให้กับวงการการแพทย์” Dr. Daniel Sahm, หัวหน้าเจ้าหน้าที่วิทยาศาสตร์ และรองประธาน Global Microbiology Services ที่ IHMA, Inc. กล่าว

เกี่ยวกับ NTS Ventures

NTS มีฐานอยู่ที่ Cleveland, OH และเป็นผู้ให้บริการพรีคลินิก บริการแบบคลินิก และบริการแบบเลื่อนที่ซึ่งได้รับการออกแบบเพื่อนำสารต่อต้านเชื้อรา สารต่อต้านแบคทีเรีย และสารตัจวิทยาสู่ตลาดโดยเริ่มตั้งแต่กระบวนการการค้นพบ NTS มีขีดความสามารถในการสนับสนุนการพัฒนายาในขั้นตอนการทดสอบพรีคลินิกและแบบคลิกเพื่อให้เป็นไปตาม Investigational New Drug (IND) และ New Drug Application (NDA) ของ FDA กว่า 25 ปีที่ผ่านมา ทีมงานของ NTS ได้เคยทำงานร่วมกับองค์กรต่างๆ หลากหลายองค์กร ซึ่งรวมถึงบริษัทเภสัชกรรมขนาดใหญ่ระดับโลก สตาร์ทอัพและบริษัทเทคโนโลยีชีวภาพที่อยู่ในระยะการเติบโต CRO แบบเต็มรูปแบบ และสถาบันการศึกษาต่างๆ

หากต้องการดูข้อมูลเพิ่มเติม โปรดไปที่ https://www.ntsventures.com

เกี่ยวกับ IHMA

IHMA มีฐานอยู่ที่ Schaumburg, IL USA และ Monthey, Switzerland และได้เป็นผู้ให้บริการการพัฒนายาต้านจุลชีพรายสำคัญมากว่า 25 ปีแล้ว อาคารปฏิบัติการของเราทั้งในสหรัฐอเมริกาและยุโรปเป็นพันธมิตรกับลูกค้าในวงการเทคโนโลยีชีวภาพ เภสัชกรรม และการตรวจวินิจฉัยทั่วโลก IHMA คือห้องปฏิบัติการอิสระชั้นนำที่เชี่ยวชาญด้านการศึกษาเชิงเฝ้าระวังและการทดลองเชิงคลินิก เป็นหมุดหมายสำคัญบนเส้นต่อเนื่องที่เชื่อมจากการพัฒนายาไปสู่การพาณิชย์ IHAM ใช้ประโยชน์จากเทคโนโลยีที่ล้ำสมัยเพื่อให้เกิดการทดสอบและข้อมูลชั้นดี พร้อมกับกรอบเศรษฐกิจที่แข็งแกร่ง การบริการของ IHMA สามารถปรับให้สอดคล้องกับความต้องการการทดสอบที่เฉพาะตัวของลูกค้าได้ นี่คือเครื่องยืนยันเส้นทางความสำเร็จด้านการพัฒนายา การพาณิชย์ และการตรวจสอบหลังออกสู่ท้องตลาด หากต้องการข้อมูลเพิ่มเติม โปรดเยี่ยมชมเว็บไซต์ของ IHMA ที่ www.ihma.com

ติดต่อขอรับข้อมูลข่าวสาร  
Brian Johnson
bjohnson@ihma.com

NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)

SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) — NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a full-service central anti-infective clinical microbiology laboratory have announced a collaborative agreement that will provide the pharmaceutical industry with a brand-new antifungal resistance surveillance program termed STAR. In addition to the expertise provided by NTS and IHMA, STAR is heavily supported through affiliations with key opinion leader (KOL) laboratories throughout the world. As antifungal resistance rises and epidemiology changes, STAR will intimately monitor fluctuations and trends in antifungal resistance and epidemiology over time. It will be an excellent tool to serve authorities, biotechnology and pharmaceutical companies in the relentless fight against antifungal drug resistance. The clinical isolates prospectively collected through STAR will include all major yeasts (including the emerging pathogen Candida auris) and filamentous fungi, such as Aspergillus spp. as well as the rarer and highly invasive mold species such as Mucor spp., Rhizopus spp., among others.

The development of new antifungal agents is increasing. Consequently, STAR will support these drugs to ensure the fight against antifungal resistance will be more efficient and to gain precious time in reducing and eventually eliminating new resistance.  The agreement between NTS and IHMA will allow all pharmaceutical and biotech companies access to the STAR program in a cost- and time-effective manner. “The STAR program is a one of a kind surveillance initiative profiling serious fungal infections, including Candida auris and Aspergillus, against common and experimental antifungals under development,” said Dr. Mahmoud Ghannoum, Founder of NTS Ventures.

“The STAR surveillance program will provide valuable information regarding serious fungal infections and provide the medical community with up to date and pertinent information regarding antifungal agents,” said Dr. Daniel Sahm, Chief Scientific Officer and VP of Global Microbiology Services at IHMA, Inc.

ABOUT NTS Ventures

NTS is based in Cleveland, OH and provides preclinical, clinical and translational services designed to bring antifungal, antibacterial and dermatology agents from discovery to market. NTS has the ability to support drug development in preclinical and clinical testing phases in order to satisfy FDA Investigational New Drug (IND) and New Drug Application (NDA) submissions. Over the past 25 years the NTS team has worked with a large range of entities including global Big Pharma, start up and growth stage biotech companies, full-spectrum CRO’s as well as academic institutions.

For more information, please visit https://www.ntsventures.com.

ABOUT IHMA

IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA’s services can be customized to best align with its clients’ unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways. For more information, visit the IHMA website at: www.ihma.com

CONTACT INFORMATION 
Brian Johnson
bjohnson@ihma.com

Philips announces exchange ratio for 2018 dividend in shares

June 12, 2019

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend in shares for the year 2018 has been determined. The exchange ratio is 1 new common share for every 41.6233 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of June 5, 6 and 7, 2019, of EUR 35.3498 and was calculated in a manner that the gross dividend in shares is approximately equal to the gross dividend in cash.

Shareholders were given the opportunity to make their choice between cash and shares between May 15, 2019 and June 7, 2019. If no choice was made during this election period, the dividend will be paid in cash. Both the dividend in cash and the dividend in shares will be made payable to shareholders from June 13, 2019.

For 41.5% of the shares, an election was made for a share dividend, resulting in the issuance of 9,079,538 new common shares. Upon payment of the dividend, the total issued share capital will amount to EUR 187,055,015.40, representing 935,275,077 common shares. After deduction of treasury shares, the total number of outstanding shares will be 909,194,188 shares (2018: 931,657,897). Philips expects to cancel approximately 30,000,000 treasury shares in June 2019.

For further information, please contact:

Martijn van der Starre
Philips Group Press Office
Tel.: +31 6 2847 4617
E-mail martijn.van.der.starre@philips.com

Ksenija Gonciarenko
Philips Investor Relations
Tel.: +31 20 5977055
E-mail: ksenija.gonciarenko@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.